AI-Driven Developability Assessment for Therapeutic Proteins, Antibodies, and Industrial Enzymes

AI-Driven Developability Assessment for Protein Engineering

The most promising protein candidate is not always the easiest one to develop.

Many proteins with excellent biological activity ultimately fail because of poor manufacturability, instability, aggregation, low expression, or formulation challenges.

Neoncorte Bio provides AI-driven developability assessment to help identify technical risks early, prioritize stronger candidates, and support efficient protein engineering and lead optimization.

What Is Developability Assessment?

Developability assessment evaluates whether a protein candidate is suitable for successful development, manufacturing, formulation, storage, and commercialization.
Rather than focusing only on biological activity, developability considers the broader set of molecular properties that influence the likelihood of technical and commercial success.
Early computational assessment enables more informed decision-making before significant laboratory and manufacturing investment.

Why Developability Matters

Poor developability is a common cause of delays and failures during protein development.
Potential issues include:
  • Low recombinant expression
  • Protein aggregation
  • Poor solubility
  • Thermal instability
  • Oxidative degradation
  • Protease sensitivity
  • High solution viscosity
  • Difficult purification
  • Limited formulation options
  • Manufacturing scalability challenges
Identifying these risks early can reduce development costs and improve project success rates.

Application Areas

AI-Driven Developability Assessment for Protein Engineering
  • Industrial Enzyme Development

    Identify stability and manufacturability risks affecting industrial enzyme production.
    Benefit: Improve commercial readiness and production efficiency.
  • Therapeutic Antibody Discovery

    Evaluate antibody candidates before lead optimization.
    Benefit: Prioritize molecules with stronger predicted developability profiles.
  • Protein Engineering

    Guide sequence optimization using computational developability insights.
    Benefit: More efficient engineering with fewer experimental iterations.
  • Biopharmaceutical Development

    Assess candidate suitability for manufacturing, formulation, and long-term development.
    Benefit: Reduced technical risk throughout the development pipeline.
  • Portfolio Prioritization

    Compare multiple candidate molecules using consistent developability metrics.
    Benefit: Better allocation of R&D resources and faster decision-making.
AI-Driven Developability Assessment for Protein Engineering

AI-Guided Developability Assessment

Neoncorte Bio combines computational protein engineering with machine learning and structural biology to evaluate multiple developability properties simultaneously.
Our workflow may incorporate:
  • Protein sequence analysis
  • Structural modeling
  • Protein language models
  • Machine learning
  • Aggregation propensity prediction
  • Solubility assessment
  • Stability prediction
  • Expression yield prediction
  • Manufacturability analysis
  • Multi-objective optimization
  • Design-Build-Test-Learn (DBTL) methodologies
  • The resulting insights help prioritize candidates and guide experimental engineering strategies.

Properties We Evaluate

Depending on project objectives, developability assessment may include:
  • Recombinant expression potential
  • Protein aggregation propensity
  • Solubility
  • Thermal stability
  • pH stability
  • Oxidative stability
  • Freeze-thaw stability
  • Protease resistance
  • Surface hydrophobicity
  • Charge distribution
  • Sequence liabilities
  • Manufacturability
  • Formulation compatibility
  • Overall developability profile
  • Assessments are tailored to the intended application and experimental objectives.
AI-Driven Developability Assessment for Proteins, Antibodies, Enzymes

Supported Protein Classes

Our workflows support a wide range of engineered proteins, including:
  • Monoclonal antibodies (mAbs)
  • Bispecific antibodies
  • Antibody-drug conjugates (ADCs)
  • Single-domain antibodies (VHH/Nanobodies)
  • Enzymes
  • Therapeutic proteins
  • Fusion proteins
  • Cytokines
  • Growth factors
  • Recombinant proteins
  • Synthetic biology proteins

Design-Build-Test-Learn (DBTL) Integration

Developability assessment is most effective when incorporated into iterative optimization.
Neoncorte Bio supports:
  1. Protein sequence analysis
  2. AI-guided developability evaluation
  3. Candidate prioritization
  4. Protein engineering
  5. Experimental validation
  6. Machine learning model refinement
  7. Successive Design-Build-Test-Learn (DBTL) cycles
This workflow accelerates optimization while reducing unnecessary laboratory work.

What Neoncorte Bio Delivers

  • AI-guided developability assessment
  • Protein sequence analysis
  • Manufacturability prediction
  • Aggregation and solubility assessment
  • Stability analysis
  • Multi-parameter protein optimization
  • Design-Build-Test-Learn (DBTL) workflows
  • Confidential B2B protein engineering partnerships

Who We Work With

  • Biopharmaceutical companies
  • Therapeutic antibody developers
  • Industrial biotechnology companies
  • Enzyme manufacturers
  • Synthetic biology startups
  • CDMOs and CROs
  • Pharmaceutical companies
  • Academic translational research groups
Frequently Asked Questions (FAQs)

Neoncorte Bio

Where AI Meets Biotechnology
Neoncorte Bio is at the forefront of the convergence between artificial intelligence and enzyme engineering. Our team comprises experts in computational biology, bioinformatics, and machine learning, all driven by a mission to accelerate innovation in enzyme design. By leveraging our advanced AI models, we provide unparalleled solutions that enhance efficiency, reduce costs, and push the boundaries of what's possible in enzyme engineering
Proud Member of Leading Global AI Programs
Neoncorte Bio is part of the NVIDIA Inception and Nebius for Startups programs — two of the world’s leading ecosystems for high-performance AI innovation. These partnerships strengthen our ability to deliver next-generation AI-driven protein, enzyme, and aptamer engineering.
  • NVIDIA Inception Neoncorte Bio AI life sciences company
    As a member of NVIDIA Inception, Neoncorte Bio gains access to cutting-edge GPU technologies, expert guidance, and a global AI ecosystem that supports companies from prototype to production. The program empowers us to explore new AI opportunities and build high-performance biological design pipelines powered by NVIDIA’s world-class platform.
  • Nebius AI life sciences Neoncorte Bio
    Through Nebius for Startups, we gain access to high-performance compute infrastructure optimized for large-scale AI workloads, along with hands-on technical guidance and a strong community of innovative AI companies. Nebius enables us to train and deploy complex biological models more efficiently — accelerating enzyme, protein, and aptamer design while supporting rapid scaling of our R&D pipelines.
Publications
Scientific Publication of Neoncorte Bio Team
  • Modification of natural enzymes to introduce new properties and enhance existing ones is a central challenge in bioengineering. This study is focused on the development of Taq polymerase mutants that show enhanced reverse transcriptase (RTase) activity while retaining other desirable properties such as fidelity, 5′-3′ exonuclease activity, effective deoxyuracil incorporation, and tolerance to locked nucleic acid (LNA)-containing substrates.
  • The transcriptomic data are being frequently used in the research of biomarker genes of different diseases and biological states. The most common tasks there are the data harmonization and treatment outcome prediction. Both of them can be addressed via the style transfer approach. Either technical factors or any biological details about the samples which we would like to control (gender, biological state, treatment, etc.) can be used as style components.
  • List of all Neoncorte Bio publications dedicated to Molecular Biology, Biotechnology, Artificial Intelligence and Artificial Neural Networks, published mostly by Nikolay Russkikh, CEO of Neoncorte Bio

Our Expertise in Action
With extensive experience in AI applications and software engineering tailored to the life sciences, we specialize in solving complex challenges and delivering innovative solutions for our customers. Our work demonstrates a deep understanding of cutting-edge technologies and their application in the real world.
Here are examples of the types of projects we have successfully delivered:
  • Automated NGS Data Analysis:
    Designed a production-grade solution for the automated processing, annotation, and analysis of Next-Generation Sequencing (NGS) data.
  • Single-Cell Data Integration:
    Built state-of-the-art tools for integrating multimodal single-cell data, achieving recognition for technical excellence.
  • Metagenomic Classification Algorithms:
    Developed advanced methods for classifying sequencing reads in metagenomics research.
  • High-Throughput Image Processing Pipelines:
    Engineered an efficient pipeline to process millions of sequencing images with exceptional accuracy.
  • Cell Counting via AI:
    Created a computer vision solution for precise cell counting in microphotography images, streamlining data analysis.
Get in touch with our team
Phone: +1-503-754-3958
Email: contact@neoncorte.com